NCT02639091 2019-11-07Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid TumorsBayerPhase 1 Completed36 enrolled
NCT02839681 2019-05-21Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung AdenocarcinomaNational Institutes of Health Clinical Center (CC)Phase 2 Terminated2 enrolled 12 charts